-
Mashup Score: 2Wegovy shows benefit even in patients with high frailty, obesity-related heart failure - 1 day(s) ago
Treatment of obesity-related HF with preserved ejection fraction with semaglutide 2.4 mg improved body weight, physical function and HF symptoms regardless of the extent of patient frailty, a speaker reported.In addition, the benefits of semaglutide 2.4 mg (Wegovy, Novo Nordisk) were strongest in those with the highest levels of frailty, according to data presented at a virtual late-breaking
Source: www.healio.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 2Wegovy shows benefit even in patients with high frailty, obesity-related heart failure - 2 day(s) ago
Treatment of obesity-related HF with preserved ejection fraction with semaglutide 2.4 mg improved body weight, physical function and HF symptoms regardless of the extent of patient frailty, a speaker reported.In addition, the benefits of semaglutide 2.4 mg (Wegovy, Novo Nordisk) were strongest in those with the highest levels of frailty, according to data presented at a virtual late-breaking
Source: www.healio.comCategories: General Medicine News, CardiologistsTweet-
Treatment of obesity-related HF with preserved ejection fraction with semaglutide 2.4 mg improved body weight, physical function and HF symptoms regardless of the extent of patient frailty @UTSWMedCenter #Cardiotwitter @EndocrineToday @HFSA #HFSA2024 https://t.co/1tRnMLfxur
-
-
Mashup Score: 5
In patients with HF and ejection fraction 40% or greater, the absolute risk reduction for total worsening HF events and CV death with finerenone vs. placebo was greatest in those with recent worsening HF, new data from FINEARTS-HF show. As Healio previously reported, in the main results of FINEARTS-HF, the nonsteroidal mineralocorticoid receptor antagonist finerenone (Kerendia, Bayer)
Source: www.healio.comCategories: General Medicine News, CardiologistsTweet-
In patients with HF and EF of 40% or more, the risk reduction for total worsening HF events and CV death with finerenone vs. placebo was greatest in those with recent worsening HF @BrighamResearch @HFSA #HFSA2024 https://t.co/9vTMqRBwc2
-
-
Mashup Score: 5
In patients with HF and ejection fraction 40% or greater, the absolute risk reduction for total worsening HF events and CV death with finerenone vs. placebo was greatest in those with recent worsening HF, new data from FINEARTS-HF show. As Healio previously reported, in the main results of FINEARTS-HF, the nonsteroidal mineralocorticoid receptor antagonist finerenone (Kerendia, Bayer)
Source: www.healio.comCategories: General Medicine News, CardiologistsTweet-
In patients with HF and EF of 40% or more, the risk reduction for total worsening HF events and CV death with finerenone vs. placebo was greatest in those with recent worsening HF @BrighamResearch @HFSA #HFSA2024 https://t.co/9vTMqRBwc2
-
-
Mashup Score: 0
The American Heart Association Scientific Sessions will be held in-person only in Chicago from Nov. 16 to 18 and will feature eight late-breaking science sessions during the 3-day meeting.The AHA announced the following late-breaking science lineup for its annual meeting.
Source: www.healio.comCategories: General Medicine News, CardiologistsTweet-
The American Heart Association Scientific Sessions will be held in-person only in Chicago from Nov. 16 to 18 and will feature eight late-breaking science sessions during the 3-day meeting #AHA2024 @American_Heart #Cardiotwitter Read moređŸ‘‡ https://t.co/G2AyIV2CKf
-
-
Mashup Score: 0Election results should not impact investment strategies - 4 day(s) ago
A common question we receive every 4 years is: How will the election impact my investments?
Source: www.healio.comCategories: General Medicine News, CardiologistsTweet-
In the latest installment of Residency to Retirement, read about how elections impact investments #cardiotwitter https://t.co/TTFOWCk4EL
-
-
Mashup Score: 0
The American Heart Association Scientific Sessions will be held in-person only in Chicago from Nov. 16 to 18 and will feature eight late-breaking science sessions during the 3-day meeting.The AHA announced the following late-breaking science lineup for its annual meeting.
Source: www.healio.comCategories: General Medicine News, CardiologistsTweet-
The American Heart Association Scientific Sessions will be held in-person only in Chicago from Nov. 16 to 18 and will feature eight late-breaking science sessions during the 3-day meeting #AHA2024 @American_Heart #Cardiotwitter Read moređŸ‘‡ https://t.co/G2AyIV2CKf
-
-
Mashup Score: 4Novel obesity agent linked to weight loss vs. placebo at 3 months in patients with HFpEF - 4 day(s) ago
In a phase 2a trial of patients with obesity-related HF with preserved ejection fraction, a novel controlled metabolic accelerator was associated with weight loss at 3 months compared with placebo. As Healio previously reported, top-line results of the phase 2a HuMain-HFpEF trial of HU6 (Rivus Pharmaceuticals), which is designed to promote weight loss while preserving muscle mass, were
Source: www.healio.comCategories: General Medicine News, CardiologistsTweet-
In a phase 2a trial of patients with obesity-related HFpEF, a novel controlled metabolic accelerator was associated with weight loss at 3 months compared with placebo @UTSWMedCenter @HFSA #HFSA2024 @EndocrineToday @GoHealio https://t.co/HFrOvyVBN4
-
-
Mashup Score: 1FDA clears software to reduce ‘guesstimation’ when assessing atherosclerotic risk - 5 day(s) ago
Elucid announced it received 510(k) clearance from the FDA for its noninvasive imaging analysis software to help quantify and classify plaque morphology and diagnose CVD.The software (PlaqueIQ) is designed to utilize first-line diagnostic coronary CT angiography to produce clinically meaningful interactive reports based on the gold standard, histology ground-truth to help visualize the plaque,
Source: www.healio.comCategories: General Medicine News, CardiologistsTweet-
Elucid announced it received 510(k) clearance from the FDA for its noninvasive imaging analysis software to help quantify and classify plaque morphology and diagnose CVD @US_FDA #Cardiotwitter #AIinMedicine https://t.co/vYhNOyghEz
-
-
Mashup Score: 4Novel obesity agent linked to weight loss vs. placebo at 3 months in patients with HFpEF - 5 day(s) ago
In a phase 2a trial of patients with obesity-related HF with preserved ejection fraction, a novel controlled metabolic accelerator was associated with weight loss at 3 months compared with placebo. As Healio previously reported, top-line results of the phase 2a HuMain-HFpEF trial of HU6 (Rivus Pharmaceuticals), which is designed to promote weight loss while preserving muscle mass, were
Source: www.healio.comCategories: General Medicine News, CardiologistsTweet-
In a phase 2a trial of patients with obesity-related HFpEF, a novel controlled metabolic accelerator was associated with weight loss at 3 months compared with placebo @UTSWMedCenter @HFSA #HFSA2024 @EndocrineToday @GoHealio https://t.co/HFrOvyVBN4
-
Treatment of obesity-related HF with preserved ejection fraction with semaglutide 2.4 mg improved body weight, physical function and HF symptoms regardless of the extent of patient frailty @UTSWMedCenter #Cardiotwitter @EndocrineToday @HFSA #HFSA2024 https://t.co/1tRnMLfxur